Article Text

Download PDFPDF
Investigation of women with endometrial carcinoma using serum vascular endothelial growth factor (VEGF) measurement
  1. R. J. Gornall1,
  2. F. W. Anthony2,
  3. E. J. Coombes1,
  4. P. Hogston1 and
  5. R. P. Woolas1
  1. 1Department of Gynaecological Oncology, St Marys Hospital, Milton Road, Portsmouth, and
  2. 2University Department of Obstetrics and Gynaecology, Princess Anne Hospital, Coxford Road, Southampton, UK
  1. Address correspondence and reprint requests to: Robert P. Woolas, Department of Gynaecological Oncology, St Marys Hospital, Milton Road, Portsmouth. PO3 6AD, UK.


This study assessed whether serum VEGF measurement in women presenting with endometrial cancer could predict advanced stage disease. Preoperative sera from 37 women undergoing laparotomy for suspected endometrial cancer were assayed for VEGF, CA125 and platelet count. Significant positive correlation was shown between VEGF and platelet levels (P = 0.003, r = 0.477). However, no correlation was demonstrated between VEGF and stage overall, and no significant difference was shown between those with early (stage 1A/1B, n = 20) compared to those with advanced (stage >1B, n = 13) or disseminated (stage >2, n = 7) disease. Serum VEGF measurement was not beneficial in the preoperative assessment of stage in patients with endometrial carcinoma. Strong correlation with platelet levels suggests that this is one of the sources of VEGF measured.

  • CA125
  • endometrial carcinoma
  • platelets
  • VEGF

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.